Last updated: February 26, 2026
What Is the Drug and Its Current Market Position?
NDC 51672-1368 refers to Fexofenadine Hydrochloride 180 mg, marketed primarily under the brand name Allegra by Sanofi. It is used to treat allergy symptoms and chronic idiopathic urticaria.
As of 2023, Allegra remains a leading second-generation antihistamine. Its sales are driven by its safety profile and over-the-counter (OTC) availability. The drug competes with other antihistamines such as cetirizine and loratadine.
Market Size and Dynamics
Market Scope
- Global allergy medication market size: Estimated at $16 billion in 2022, with a projected CAGR of 5.2% over the next five years (MarketWatch, 2023).
- US allergy medication segment (including antihistamines): $4.5 billion in 2022.
- OTC segment: Accounts for approximately 70% of antihistamine sales, indicating broad consumer access.
Factors Influencing Market
- Expanded OTC availability increases accessibility.
- Rising prevalence of allergic rhinitis; estimated 20-30% of the population affected globally.
- Growth in aging populations heightens demand for allergy treatments.
Competitive Landscape
- Main competitors: Loratadine (Claritin), Cetirizine (Zyrtec), and newer agents like bilastine.
- Patent expiry: Allegra's patent expired in 2011, leading to generic versions.
Generics and Market Share
- Generic availability has significantly reduced prices.
- In 2022, generics accounted for over 75% of Allegra's prescriptions in the US.
- The sales share of branded Allegra decreasing, with generics capturing majority market demand.
Pricing Trends and Forecast
Current Pricing (2023)
| Formulation |
Average Retail Price (ARV) per Tablet |
Wholesale Acquisition Cost (WAC) |
| Allegra 180 mg tablets |
$2.50 |
$1.90 |
| Generic 180 mg tablets |
$0.70 |
$0.50 |
- Brand-name product retail prices are 3.5 times higher than generics.
- WAC shows a consistent decline due to increased generic market penetration.
Price Trajectory (Next 5 Years)
| Year |
Expected ARV for Brand (Estimated) |
Expected WAC (Estimated) |
| 2023 |
$2.50 |
$1.90 |
| 2024 |
$2.40 |
$1.80 |
| 2025 |
$2.30 |
$1.70 |
| 2026 |
$2.25 |
$1.60 |
| 2027 |
$2.20 |
$1.50 |
- Price declines reflect market saturation with generics.
- Brand name prices are expected to stabilize around a 12% discount to current levels, as manufacturers attempt to sustain profitability.
Impact of Regulatory and Policy Changes
- Increased OTC access lowers barriers but pressures brand prices.
- Policy moves toward price regulation or reimbursement caps could further compress margins.
Revenue Projections
Assumptions
- US market represents 60% of total sales.
- Market share: 25% for branded Allegra; 75% for generics.
- Annual prescriptions: 15 million.
- Average price per prescription (brand): $75; generic: $20.
Revenue Breakdown (2023)
| Segment |
Prescriptions |
Price per Prescription |
Revenue (Millions USD) |
| Branded Allegra |
3.75 million |
$75 |
$281 |
| Generics |
11.25 million |
$20 |
$225 |
| Total US |
15 million |
|
$506 |
Future Revenue Trends (2024-2027)
| Year |
Total US Revenue (Millions USD) |
Growth Rate |
Notes |
| 2024 |
$480 |
-5% |
Slight drop as generic price pressure intensifies |
| 2025 |
$460 |
-4% |
Continued generic consolidation |
| 2026 |
$445 |
-3% |
Market saturation persists |
| 2027 |
$430 |
-3% |
Declining brand share, stable generics |
Strategic Influences
- R&D investments in new formulations or combination products could alter market dynamics.
- Generic manufacturers lowering prices could erode margins.
- Potential regulatory shifts, such as new OTC switches, may influence volume and pricing.
Key Takeaways
- The drug's market remains dominated by generics due to patent expiry since 2011.
- Generic prices expected to decline further; branded prices will stabilize but decline marginally.
- US market sales are projected to decrease slightly over the next five years due to market saturation and price competition.
- Revenue from branded Allegra will decrease gradually but remain significant due to brand loyalty among certain patient groups.
- Future growth relies on whether manufacturers innovate or expand indications.
FAQs
1. What factors primarily influence Allegra's market price?
Generic availability, market saturation, OTC accessibility, and regulatory policies.
2. How might patent protections or exclusivity periods impact prices?
Patent protections historically sustain higher prices; their expiration leads to price erosion due to generics.
3. What is the competitive advantage of Allegra over its competitors?
Brand recognition, perceived efficacy, and safety profile. However, generics dominate due to lower prices.
4. How does OTC availability affect pricing?
Increases accessibility, leading to competitive pricing and pressure on branded prices.
5. What are the prospects for new formulations or indications?
Potential exists, but current data show minimal innovation activity; market expansion depends on ongoing R&D efforts.
References
[1] MarketWatch. (2023). Global allergy medications market report. Retrieved from https://www.marketwatch.com
[2] IQVIA. (2022). US prescription drug market analysis.
[3] FDA. (2022). List of drug patents and exclusivity periods.
[4] OTC Medicine Price Index. (2023). 2023 report on allergy medication prices.
[5] Statista. (2023). Antibiotic and allergy drug market projections.
